KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Short term Debt: 2010-2020

Historic Short term Debt for Emergent BioSolutions (EBS) over the last 5 years, with Jun 2020 value amounting to $22.3 million.

  • Emergent BioSolutions' Short term Debt fell 59.16% to $22.3 million in Q2 2020 from the same period last year, while for Jun 2020 it was $22.3 million, marking a year-over-year decrease of 59.16%. This contributed to the annual value of $3.2 million for FY2019, which is 68.32% down from last year.
  • Per Emergent BioSolutions' latest filing, its Short term Debt stood at $22.3 million for Q2 2020, which was up 596.88% from $3.2 million recorded in Q4 2019.
  • In the past 5 years, Emergent BioSolutions' Short term Debt registered a high of $62.7 million during Q1 2019, and its lowest value of $3.2 million during Q4 2019.
  • Its 3-year average for Short term Debt is $34.8 million, with a median of $38.5 million in 2019.
  • Data for Emergent BioSolutions' Short term Debt shows a maximum YoY plummeted of 68.32% (in 2019) over the last 5 years.
  • Quarterly analysis of 3 years shows Emergent BioSolutions' Short term Debt stood at $10.1 million in 2018, then crashed by 68.32% to $3.2 million in 2019, then slumped by 59.16% to $22.3 million in 2020.
  • Its Short term Debt was $22.3 million in Q2 2020, compared to $3.2 million in Q4 2019 and $55.7 million in Q3 2019.